513 results on '"Nevill, Thomas"'
Search Results
52. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*
53. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation
54. Hematopoietic stem cell transplantation: a primer for the primary care physician
55. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
56. Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents
57. Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial
58. Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS
59. Maintenance therapy with either Lenalidomide or Bortezomib equally improves PFS and OS in High Risk Myeloma initially treated with Autotransplant.
60. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission
61. Myelodysplastic syndrome and a nonrandom chromosomal abnormality t(1;19):: an indolent pathologic entity
62. Majocchi's granuloma in a patient with GATA2 haploinsufficiency undergoing hematopoietic stem cell transplantation.
63. Anti-Thymocyte Globulin for Patients Undergoing Hematopoietic Cell Transplantation from Unrelated Donors: A Randomized, Controlled, Open-Label, Phase 3, Multicentre Trial from Cell Therapy Transplant Canada
64. Older Adults with Acute Myeloid Leukemia in Rural Areas Are Less Likely to Receive Azacitidine with Worsened Overall Survival
65. Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population
66. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab
67. Outpatient Autologous Stem Cell Transplants for Multiple Myeloma—Analysis of Safety and Outcomes in a Tertiary Care Centre
68. Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada
69. Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes
70. Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia
71. Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide
72. Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements
73. Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia
74. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study
75. Pre-Transplant Vitamin D Deficiency is Associated with Inferior Overall Survival but not Associated with Relapse Free Survival or Cumulative Incidence of GVHD Post Adult Hematopoietic Cell Transplantation for Hematological Malignancies
76. 27 - Outpatient Autologous Stem Cell Transplants for Multiple Myeloma—Analysis of Safety and Outcomes in a Tertiary Care Centre
77. Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus
78. Pediatric-Based Versus Adult Treatment Protocols in Young Adults (18-40 years) with Standard Risk Acute Lymphoblastic Leukemia: The BC Cancer Agency Experience
79. Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study
80. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation
81. Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis
82. Predictive Factors of Overall Survival and the Completion of Four Cycles of Azacitidine: An MDS-CAN Study
83. An MDS Specific Frailty Index Based on Cumulative Deficits Adds Independent Prognostic Value to Established Clinical Prognostic Scoring Systems
84. Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.
85. Rediscovering a forgotten voice: The percussion ensemble music of Johanna Magdalena Beyer
86. Patient Related Factors Have an Indepedent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry
87. Prognostic Factors and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Vs. Non-Transplant Chronic Lymphocytic Leukemia (CLL) Patients: A Comparative Analysis with the Leukemia/BMT Program of British Columbia (BC) and the BC Provincial CLL Database
88. Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial
89. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Failing Treatment with Tyrosine Kinase Inhibitors
90. Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia
91. Improved Survival In Adults With Mixed-Phenotype Acute Leukemia Following Stem Cell Transplantation (SCT): A Single Centre Experience
92. Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort
93. Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy
94. Successful allogeneic bone marrow transplantation (BMT) following orthotopic liver transplantation (OLT) for fulminant hepatic failure and severe aplastic anemia (SAA) due to non A non B non C hepatitis
95. Elderly AML Patients Treated with Intensive Chemotherapy- Developing A Prognostic Scoring System. A Study On 381 Patients From British Columbia
96. Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG
97. Reduced Incidence of Early Invasive Fungal Infection in Allogeneic Transplant Patients Following Micafungin Prophylaxis
98. Outcomes for Patients Aged 60 and Over Are Similar to Younger Patients Following Reduced-Intensity Allogeneic Stem Cell Transplant for CLL
99. Clonal Evolution but Not Variant Chromosomal Translocations Is An Adverse Prognostic Marker for Cytogenetic Response and Survival in CML Patients Treated with Imatinib
100. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.